Bio-Path Holdings, Inc. · OTC:BPTH
Bio-Path — Shareholder Meeting (December 2020)
16 slides from Bio-Path's shareholder meeting presentation, Dec 21, 2020
Slide 1: Bio-Path Holdings Annual Shareholder Meeting December 2020
Bio-Path Holdings An Oncology-Focused Biotechnology Company Annual Shareholder Meeting December 2020
Slide 2: Forward looking statements
Forward looking statements This Presentation contains forward-looking statements with respect to business conducted by Bio-Path Holdings, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will
Slide 3: Introducing Bio-Path Holdings
Introducing Bio-Path Holdings Advanced Oligonucleotide Therapeutics with High Efficiency Systemic Delivery Publicly traded Employees, Established NASDAQ Contractors & Houston, TX Consultants BPTH 2007 14 Technology Highlights ® DNAbilize Technology, next generation single-stranded DNA antisense Robu
Slide 4: Robust Oncology Pipeline
Robust Oncology Pipeline Preclinical IND PHASE 1 PHASE 2 Prexigebersen (BP1001, Liposomal Grb2) AML* *Orphan drug designation from the USFDA and Prexigebersen-A (BP1001-A) Solid Tumors (ovarian, endometrial, EMA for AML pancreatic) BP1002 (Liposomal Bcl-2) Lymphoma, CLL BP1002 (Liposomal Bcl-2) AML
Slide 5: DNAbilize Technology
DNAbilize Technology ® Proven As Safe, Robust and Targeted Method for Treating Disease No Toxicity No Toxicity With human patients to date in prexigebersen clinical trial. • DNAbilize™ liposome structure is similar to the cellular membrane • P-ethoxy DNA does not induce hepatotoxicity or thrombocyto
Slide 6: Stage 1 of the Phase 2 Efficacy Trial Design for AML Prexigebersen Combination Therapy
Stage 1 of the Phase 2 Efficacy Trial Design for AML Prexigebersen Combination Therapy • Treatment of untreated AML patients who are induction therapy ineligible and unfit for stem cell transplant • Efficacy trial conducted at 6 leading cancer centers in the U.S., including the MD Anderson Cancer Ce
Slide 7: Safety Segment Phase 2 Prexigebersen + LDAC Combination Therapy Showed Excellent Results
Safety Segment Phase 2 Prexigebersen + LDAC Combination Therapy Showed Excellent Results Relapsed/refractory AML patients - 3 evaluable patients per cohort, 2 cohorts, n=6 - Dose 60 mg/m2 and 90 mg/m2 respectively - Received drug 2x week for 4 weeks per treatment cycle Results - 3 patients achieved
Slide 8: Results of Stage 1 Interim Analysis
Results of Stage 1 Interim Analysis Patient evaluation summary 5 Patients achieved CR (30%) Note: LDAC alone CR rate 7-13% 6 Patients achieved stable disease (35%) +65% 17 2 Stable disease patients had >50% bone marrow blasts reductions 1 CR patient was eligible for and received a bone marrow transp
Slide 9: Prexigebersen-A Phase 1 Study in Solid Tumors
Prexigebersen-A Phase 1 Study in Solid Tumors • Prexigebersen-A is a modified product that incorporates the same drug substance as prexigebersen but has a slightly modified formulation designed to enhance nanoparticle properties • Prexigebersen-A efficacy against ovarian tumors was enhanced when com
Slide 10: BP1002 – A Phase 1 Study in Lymphoma and CLL
BP1002 – A Phase 1 Study in Lymphoma and CLL • BP1002 is an RNAi antisense nanoparticle targeting Bcl-2 • BP1002 decreased viability of lymphoma cells (11 of 15 lymphoma cell lines) • By blocking Bcl-2 protein expression, BP1002 allows chemotherapy and radiation to activate apoptosis • BP1002 extend
Slide 11: BP1003 Targeting STAT3
BP1003 Targeting STAT3 • BP1003 has efficacy against non-small cell lung cancer, AML, and pancreatic cancer cells • BP1003 + gemcitabine combination is efficacious in pancreatic cancer-derived tumors in animals • IND enabling studies during 2020 - 2021 • Goal is to submit a new IND in 2021 • Conduct
Slide 12: Experienced Leadership Team
Experienced Leadership Team Officer and Director Peter Nielsen since founding Michael Hickey 20+ years experience across all phases of drug Co-Founder, President, Company in 2007 Director Clinical development Chief Executive Officer Program Management and Chief Financial Manufacturing Officer Point
Slide 13: Scientific Advisory Board
Scientific Advisory Board Jorge Cortes, M.D. • Director, Cancer Center at Augusta University • Georgia Research Alliance Eminent Scholar in Cancer Chairman • Formerly, Jane and John Justin Distinguished Chair in Leukemia Research, Chief of the AML and CML sections, and Deputy Chair of the Department
Slide 14: IP and Financial Snapshot
IP and Financial Snapshot Intellectual Property • Original patents licensed from MD Anderson • New composition and methods of use patent issued covers DNAbilize® technology, solely owned by Bio-Path • Second patent issued for composition and methods with additional claims granted • Five additional p
Slide 15: Accomplishments in 2020
Accomplishments in 2020 Successfully completed preclinical efficacy studies for the triple combination treatment of prexigebersen, decitabine and venetoclax in AML cell lines, suggesting significant enhancement in the efficacy of the frontline treatment. Presented a poster at the 2020 American A
Slide 16: Thank you
Bio-Path Holdings Thank you Bio-Path Holdings, Inc. 4710 Bellaire Blvd Suite 210 Bellaire, TX 77401 Web: www.biopathholdings.com Mail: partnering@biopathholdings.com Tel: (832) 742-1369 16
Bio-Path Holdings — Shareholder Meeting (December 2020) on 6ix